NASDAQ: RLMDRelmada Therapeutics Inc Stock Ownership - Who owns Relmada Therapeutics?
Insider buying vs selling
Have Relmada Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Maged Shenouda | Chief Financial Officer | 2025-12-15 | 11,665 | $4.12 | $48.06kBuy |
| Sergio Traversa | Chief Executive Officer | 2025-12-15 | 27,500 | $4.12 | $113.30kBuy |
| Chuck Ence | CAO and COO | 2025-11-05 | 136,000 | $2.20 | $299.20kBuy |
| Paul Edward Kelly | Chief Operating Officer | 2025-11-05 | 90,000 | $2.20 | $198.00kBuy |
| Maged Shenouda | Chief Financial Officer | 2025-11-05 | 500,000 | $2.20 | $1.10MBuy |
| Sergio Traversa | Chief Executive Officer | 2025-11-05 | 272,500 | $2.20 | $599.50kBuy |
RLMD insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when RLMD insiders and whales buy or sell their stock.
RLMD Shareholders
What type of owners hold Relmada Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Sergio Traversa | 1.22% | 1,300,000 | $5.68M | Insider |
| Maged Shenouda | 0.75% | 800,000 | $3.50M | Insider |
| Paul Edward Kelly | 0.47% | 502,295 | $2.20M | Insider |
| Chuck Ence | 0.38% | 403,931 | $1.77M | Insider |
| Nabil Yazgi | 0.17% | 185,000 | $808.45k | Insider |
| Sandesh Seth | 0.12% | 123,258 | $538.64k | Insider |
| Eric Thomas Schmidt | 0.09% | 100,000 | $437.00k | Insider |
| John Glasspool | 0.07% | 75,000 | $327.75k | Insider |
| Charles J. Casamento | 0.03% | 31,484 | $137.59k | Insider |
| Juptop | 0.01% | 11,165 | $48.79k | Institution |
RLMD vs Biotech Stocks
Relmada Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.